Entrepreneur India’s Post

Levodopa-induced Dyskinesia Market Growth Anticipated by 2032 | Companies includes Adamas Pharmaceuticals, Acorda Therapeutics, Impel NeuroPharma, Neurocrine Biosciences, Kyowa Kirin, Sunovion Pharma: Levodopa-induced Dyskinesia Market DelveInsight’s analysts project market growth, fueled by increasing prevalence, improved diagnostics, advancements in drug development, and the expected launch of innovative therapies. The market for Levodopa-induced Dyskinesia is poised for significant growth from 2019 to 2032, according … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

🚀 Exciting news from the pharmaceutical industry! ReviR Therapeutics, based in #Brisbane, has successfully closed a $30 million Series A #financing round, boosting its total #funding to an impressive $54 million. This substantial #investment, primarily from Lapam Capital and supported by existing investors such as CDH Investments and 5Y Capital, underscores the growing confidence in #ReviR’s innovative approach. The company is dedicated to advancing small molecule RNA modulators specifically designed for #neurogenetic diseases, leveraging cutting-edge artificial #intelligence to drive their #researchanddevelopment efforts. The implications of this funding are significant. As #ReviR Therapeutics pushes the boundaries of what’s possible in treating complex #neurogenetic conditions, we can expect to see transformative advancements in #personalizedmedicine and #drug #development. This development not only highlights the potential for AI-driven breakthroughs but also sets a new benchmark for investment and innovation within the industry. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #ReviRTherapeutics #AIinPharma #NeurogeneticDiseases #PharmaIndustry #pharmaceutical #pharmaceuticalindustry #healthcare

Biopharmaceutical companies that develop cancer treatments bring hope to millions of patients, and often profit handsomely along the way. However, while shareholders are eager for positive news about a company’s prospects, misrepresenting regulatory statements in the pharmaceutical industry—where lives are on the line—is exceedingly dangerous. Pomerantz recently achieved a $19.65 million settlement in a shareholder suit against Y-mAbs Therapeutics, Inc., a clinical biopharmaceutical company specializing in antibody-based therapies. According to the complaint, Y-mAbs misrepresented the FDA’s concerns about certain data in the company’s approval application for its neuroblastoma treatment, omburtamab, misleading investors into believing that omburtamab was on track for approval when in fact the FDA had identified serious issues with the data used as a control group in a study of the drug’s efficacy. When the FDA denied approval for omburtamab, the company's stock price sharply declined, resulting in significant losses for investors. #MedicalInnovation #PharmaceuticalIndustry #InstitutionalInvestors #SecuritiesLitigation #ClassAction

#Phispers Week 47 - Weekly Pharma News Recap Sponsored by Valsynthese - Merck inks strategic deal with China’s LaNova for up to US$ 3.3 bn for cancer drug. - Vaccine makers’ stocks tumble after Trump picks RFK Jr. as health secretary. - Syndax Pharmaceuticals wins first FDA nod for new class of leukemia drugs. - FDA busts Chinese drugmaker’s attempt to hide data in warning letter. #Phispers this week - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass https://lnkd.in/dFgR_X6k

𝐏𝐑𝐈𝐒𝐌 𝐁𝐢𝐨𝐥𝐚𝐛 𝐚𝐧𝐝 𝐎𝐧𝐨 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐫𝐠𝐞 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐟𝐨𝐫 𝐍𝐨𝐯𝐞𝐥 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 PRISM Biolab PRISM BioLab Co., Ltd. announces a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO.ONO PHARMACEUTICAL CO., LTD., LTD. The collaboration aims to create a development candidate for Ono's oncology target using PRISM's PepMetics® technology. PRISM will license its rights to Ono for clinical development and commercialization upon candidate identification. The agreement includes upfront payments, milestones, royalties, and other terms. Seishi Katsumata Seishi Katsumata, Executive Director, Discovery & Research of Ono, expressed appreciation for PepMetics® technology, highlighting its potential to address unmet medical needs. Dai Takehara Dai Takehara, President & CEO of PRISM Biolab, emphasized the innovative potential of the collaboration. The partnership aims to produce game-changing drugs benefiting patients. #BiotechPartnership #OncologyTreatment #ResearchAndDevelopment #DrugDevelopment #Partnership #Agreement #Collaboration

#Phispers Week 20 - Weekly Pharma News Recap Sponsored by SPI Pharma Bonjour, - France draws US$ 2.25 bn investment from Sanofi, Pfizer, AstraZeneca, GSK. - Sanofi bails out Novavax, pays US$ 1.2 bn to commercialize, develop Covid jabs. - AbbVie, Gilgamesh Pharmaceuticals ink deal to develop psychedelic drugs for psychiatric conditions. - FDA expands use of Bristol Myers Squibb’s Breyanzi to treat follicular lymphoma. #Phispers in a minute - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

Otsuka Pharmaceutical to Acquire Jnana Therapeutics for Up to $1.1 Billion Deal Consideration: Otsuka Pharmaceutical has entered into an agreement to acquire Boston-based Jnana Therapeutics for more than $1 billion. The deal consists of an $800 million upfront payment to Jnana’s shareholders, with an additional $325 million contingent on achieving specific development and regulatory milestones. Acquisition Rationale: Jnana Therapeutics is a clinical-stage biotech company specializing in rare genetic disorders. Its lead program, JNT-517, is a potential treatment for phenylketonuria (PKU), a rare metabolic disease. By acquiring Jnana, Otsuka is strengthening its research and development capabilities, particularly in the field of rare diseases, and expanding its presence in the U.S. biotech hub. This strategic acquisition aligns with the broader trend of Japanese pharma giants, such as Ono Pharma, Takeda, and Astellas, making substantial overseas investments to diversify and bolster their global drug portfolios. Otsuka, widely known for its leadership in psychiatric medications like Abilify and its oncology treatments, is now further broadening its R&D focus to include cutting-edge therapies for rare diseases. Looking Ahead: As Otsuka continues to grow its global footprint, this acquisition demonstrates a strong commitment to innovation and expanding its therapeutic areas beyond traditional sectors. #OtsukaPharmaceutical #JnanaTherapeutics #Biotech #PharmaNews #Acquisition #HealthcareInnovation #DrugDevelopment #LifeSciences #PharmaceuticalIndustry #RareDiseases #BiotechGrowth

DelveInsight’s analysis shows strong growth in the SERD market across the 7MM, driven by ORSERDU’s uptake in ESR1 mutated metastatic HR+/HER2- patients, Faslodex generics, and the expected launch of oral SERDs. By 2034, ORSERDU, camizestrant, giredestrant, and imlunestrant are forecasted to generate USD 3 billion in the US metastatic settings alone. Key players like Stemline Therapeutics, Roche, AstraZeneca, and Eli Lilly and Company are leading the development of next-gen oral SERDs, with pipeline drugs such as Giredestrant, Camizestrant, and Imlunestrant. Early-stage players like InventisBio and Zenopharm are also emerging. In 2023, the US saw 55,000 metastatic HR+/HER2- cases, highlighting a large addressable market. Get more details here: https://lnkd.in/ga8htYZ6 #SERDMarket #BreastCancerTreatment #Oncology #AstraZeneca #Stemline #Roche #Lilly #Camizestrant #Giredestrant #Imlunestrant #Biotech #ClinicalTrials #DelveInsight #MedicalResearch #HealthcareInnovation #PharmaDevelopment #PharmaNews #marketgrowth #marketforecast #healthcare #healthcareconsulting #marketresearch #healthcare #pharmaceutical #business DelveInsight Business Research LLP

#Phispers Week 47 - Weekly Pharma News Recap Sponsored by Valsynthese - Merck inks strategic deal with China’s LaNova for up to US$ 3.3 bn for cancer drug. - Vaccine makers’ stocks tumble after Trump picks RFK Jr. as health secretary. - Syndax Pharmaceuticals wins first FDA nod for new class of leukemia drugs. - FDA busts Chinese drugmaker’s attempt to hide data in warning letter. #Phispers in a minute - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

#Announcement Trillioni Pharma achieves a new milestone! In line with our ongoing commitment to expanding pharmaceuticals to meet the diverse needs of our clients, we announce our strengthened presence in Germany through a new partnership with an EU GMP-certified manufacturer specialized in oncology products. With each new partnership, we enhance our role in streamlining communication between buyers and pharmaceutical manufacturers worldwide. Contact us for further inquiries and discuss your investment options. www.trillionipharma.com info@trillionipharma.com #Pharma #Trillioni #TrillioniPharma #TrillioniPlatform #TrillioniPharmaPlatform #PharmaceuticalManufacturing #Manufacturing #PharmaceuticalProducts #Medicine #Health #HealthCare #Germany #Partnership #GlobalNetWork #NewDeals #GMP #EU #Oncology #Oncological